{"id":"NCT03324776","sponsor":"Model Clinical Research LLC","briefTitle":"Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients","officialTitle":"Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-16","primaryCompletion":"2020-06-10","completion":"2020-06-10","firstPosted":"2017-10-30","resultsPosted":"2024-06-26","lastUpdate":"2024-06-26"},"enrollment":20,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type2 Diabetes"],"interventions":[{"type":"DRUG","name":"Afrezza Inhalant Product","otherNames":["Afrezza Inhaled Insulin"]}],"arms":[{"label":"Addition of mealtime Afrezza Inhalation Powder","type":"OTHER"}],"summary":"To examine the effects of adding prandial Afrezza inhaled insulin to patients with type 2 diabetes who are not controlled after at least 6 months of other diabetes treatments including oral agents, basal insulin, or GLP-1 use.","primaryOutcome":{"measure":"Change in Percentage of HbA1c From Baseline to 3 Months","timeFrame":"Baseline to 3 months","effectByArm":[{"arm":"Addition of Mealtime Afrezza Inhalation Powder","deltaMin":1.6,"sd":0.247}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":11},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":[]}}